[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622721":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":20,"responsibleParty":32,"collaborators":20,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":20,"eligibilityCriteria":40,"healthyVolunteers":36,"sex":41,"minAge":42,"maxAge":43,"enrollmentInfo":44,"targetDuration":20,"studyType":47,"phases":48,"briefSummary":50,"conditions":51,"keywords":20,"overallStatus":53,"whyStopped":20,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":20},{"fullName":5,"class":6},"Linno Pharmaceuticals, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"SLN 12140 will be administered subcutaneously .","EXPERIMENTAL","5 participants will receive SLN12140 100mg QW for 4 weeks, then 300mg QW for 8 weeks, then 200mg QW for 52 weeks.\n\n5 participants will receive SLN12140 200mg QW for 4 weeks, then 600mg Q4W for 60 weeks",[13],"Drug: SLN12140",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","SLN12140","5 participants will receive SLN12140 100mg QW for 4 weeks, then 300mg QW for 8 weeks, then 200mg QW for 52 weeks. 5 participants will receive SLN12140 200mg QW for 4 weeks, then 600mg Q4W for 60 weeks",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Hong Yan Tong, Professor","CONTACT","86+13958122357","hongyantong@aliyun.com",{"name":28,"role":24,"phone":29,"phoneExt":30,"email":31},"Feng Kui Zhang, Professor","86+","13821700281","fkzhang@ihcams.ac.cn",{"type":33,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100622721","phase-2-sln12140-in-adult-participants-with-paroxysmal-nocturnal-hemoglobinuria-pnh-in-china-100622721",false,"NCT07387302","SLN12140 in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China","A Phase II Clinical Study Evaluating SLN12140 in Complement Inhibitor-Naïve Adult Subjects With Paroxysmal Nocturnal Hemoglobinuria","Inclusion Criteria:\n\n* Adult complement inhibitor naïve PNH patients (age\\>=18), which is confirmed by flow cytometry evaluation\n* Must be vaccinated against meningococcal vaccine and pneumococcal vaccine\n\nExclusion Criteria:\n\n* Significant bone marrow failure\n* Meningitidis infection or unresolved meningococcal disease\n* Other significant systemic diseases that might have impact on efficacy and safety assessment","ALL","18 Years","80 Years",{"count":45,"type":46},10,"ESTIMATED","INTERVENTIONAL",[49],"PHASE2","The goal of this clinical trial is to learn if drug SLN12140 works to treat Complement Inhibitor-Naïve Subjects with Paroxysmal Nocturnal Hemoglobinuria in adults. It will also learn about the safety, pharmacokinetic characteristics, and dosing of drug SLN12140.\n\nThe study is divided into four phases: screening period, core treatment period, extended dosing period, and follow-up period, and includes two cohorts (Cohorts 1-2), with each cohort enrolling at least 5 treatment-naïve adult PNH subjects for complement inhibitor therapy.",[52],"Paroxysmal Nocturnal Hemoglobinuria (PNH)","NOT_YET_RECRUITING","2026-01-27",{"date":56,"type":57},"2026-02-04","ACTUAL",{"date":59,"type":46},"2026-02-10",{"date":61,"type":46},"2027-12-31",{"name":5,"class":6}]